Bioasis Technologies partners with Oxyrane to evaluate combining brain therapy technologies

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) reports that it will enter a research collaboration with Oxyrane UK Ltd. The Guilford, Connecticut-based Bioasis is a pre-clinical, research-stage biopharmaceutical company developing a proprietary xB3 platform technology for the delivery of therapeutics across the blood-brain barrier (BBB). As well as the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The research collaboration will focus on combining xB3 technology and Oxyrane’s OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain. READ: Bioasis strikes convertible security funding agreement for institutional investment of up to C$10M UK-based Oxyrane is developing enhanced enzyme replacement therapies (ERT) for lysosomal storage diseases (LSDs) using a proprietary, glycoengineered yeast expression system for efficient targeting of enzymes to the lysosome. “We are excited to be collaborating with Oxyrane on this initiative to evaluate the combination of both our technologies to meet an unmet need for patients with LSDs for enzyme replacement therapies with greater efficacy,” Bioasis Executive Chair Dr Deborah Rathjen said in a statement. She continued: “Bioasis’ technology has demonstrated preclinical success in delivering enzyme replacement therapy into the brain and the aim of this collaboration is to fast track the development of a next generation approach to enzyme replacement therapy with the potential for improved peripheral activity combined with brain penetrance to address neurological symptoms.” Oxyrane CEO Dr Wouter Vervecken also offered insight into the research partnership. “We have been impressed by Bioasis’ technology for BBB delivery of enzyme replacement therapy and our technologies are very complementary so this collaboration is a natural fit. Oxyrane’s technology produces ERTs with enhanced cellular uptake and superior pharmacodynamics in a cost-efficient manner which we believe will be an overall benefit to patients,” said Vervecken.  Contact the writer at georgia@proactiveinvestors.com Follow her on Twitter @MissInformd